Keynote 158, 2022

Question 1

Study question for Keynote 158?

Answer 1

Ph II basket trial; safety and activity in multiple cancer types - reporting MSI-H/dMMR

Question 2

Study design for Keynote 158?

Answer 2

Pembro q 3 weeks. ORR with RECIST; DOR, PFS, OS and safety

Cohort D - endometrial cancer
Cohort K - any MSI-H/dMMR solid tumor

Question 3

Results for Keynote 158?

Answer 3

ORR - 48%
Median DOR - not reaches
PFS - 13.1 mo
OS - median not reached